Literature DB >> 17555423

Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.

H Miwa1, M Sasaki, T Furuta, T Koike, Y Habu, M Ito, Y Fujiwara, T Wada, A Nagahara, M Hongo, T Chiba, Y Kinoshita.   

Abstract

BACKGROUND: Few studies have compared the efficacy of proton pump inhibitors in resolving the symptoms of non-erosive reflux disease (NERD) and of erosive gastro-oesophageal reflux disease (GERD) in Japan. AIM: To investigate and compare the efficacy of 4-week course of rabeprazole 10 mg/day on symptom resolution in NERD and erosive GERD in Japan.
METHODS: The modified Los Angeles classification was used to grade endoscopically GERD in patients with heartburn (Grades N and M: NERD, Grades A and B: mild reflux oesophagitis (RO), and Grades C and D: severe RO). Rabeprazole 10 mg/day was administered for 4 weeks to 180 patients who kept symptom diaries.
RESULTS: Complete relief of the symptoms was achieved in 35.8% of the NERD group and 55.4% of the erosive GERD group (mild RO: 51.1% and severe RO: 77.8%). Rabeprazole was significantly more effective in erosive GERD than in NERD patients. Among the NERD subgroups (Grades N and M), no difference in symptom improvement was observed.
CONCLUSIONS: Four-week, rabeprazole 10 mg/day acid suppression therapy was effective in resolving symptoms in Japanese GERD patients. This therapy was more effective in erosive GERD than in NERD patients, and in those with severe RO than in those with mild RO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555423     DOI: 10.1111/j.1365-2036.2007.03350.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  27 in total

1.  Treatment of Refractory Gastroesophageal Reflux Disease.

Authors:  Rishi D Naik; Matthew H Meyers; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

2.  A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.

Authors:  Kyoichi Adachi; Kenji Furuta; Hiroto Miwa; Tadayuki Oshima; Masaharu Miki; Yoshinori Komazawa; Katsuhiko Iwakiri; Takahisa Furuta; Tomoyuki Koike; Tomohiko Shimatani; Yoshikazu Kinoshita
Journal:  Dig Dis Sci       Date:  2012-02-26       Impact factor: 3.199

3.  Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.

Authors:  Yoshikazu Kinoshita; Shunji Ishihara
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

Review 4.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

5.  Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.

Authors:  Kiyoshi Ashida; Yoshikazu Kinoshita; Michio Hongo
Journal:  Dig Dis Sci       Date:  2011-02-08       Impact factor: 3.199

6.  Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.

Authors:  Mitsushige Sugimoto; Naohito Shirai; Masafumi Nishino; Chise Kodaira; Takahiro Uotani; Shu Sahara; Hitomi Ichikawa; Takuma Kagami; Ken Sugimoto; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2014-07-06       Impact factor: 2.953

7.  Reply to the letter by E. Savarino et al. regarding "The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders".

Authors:  Yoshikazu Kinoshita; Hiroto Miwa; Katsuyuki Sanada; Koji Miyata; Ken Haruma
Journal:  J Gastroenterol       Date:  2014-06-29       Impact factor: 7.527

8.  Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.

Authors:  Takahisa Furuta; Tomohiko Shimatani; Mitsushige Sugimoto; Shunji Ishihara; Yasuhiro Fujiwara; Motoyasu Kusano; Tomoyuki Koike; Michio Hongo; Tsutomu Chiba; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2011-08-24       Impact factor: 7.527

9.  Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa.

Authors:  Hiroto Miwa; Junichi Koseki; Tadayuki Oshima; Takashi Kondo; Toshihiko Tomita; Jiro Watari; Takayuki Matsumoto; Tomohisa Hattori; Kunitsugu Kubota; Seiichi Iizuka
Journal:  J Gastroenterol       Date:  2009-12-18       Impact factor: 7.527

10.  Brief Questioning by Nursing Staffs before Endoscopic Examination May Not Always Pick Up Clinical Symptoms of Endoscopic Reflux Esophagitis.

Authors:  Tooru Takashima; Kanako Yamaguchi; Megumi Hara; Tomoko Fukuda; Tsukasa Kuroki; Chie Furushima; Ruriko Wakeshima; Ryuichi Iwakiri; Kazuma Fujimoto; Norie Inoue
Journal:  J Clin Biochem Nutr       Date:  2010-04-10       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.